GeneScience Pharmaceuticals Co., Ltd.

What GeneScience Pharmaceuticals Co., Ltd. does

GeneScience Pharmaceuticals Co., Ltd. (长春金赛药业有限责任公司) is a Chinese biopharmaceutical company founded in 1998 and headquartered in Changchun, Jilin Province. The firm operates as a majority-owned subsidiary of publicly listed Changchun High-Tech (SZSE: 000661) and develops biologics and innovative drugs spanning recombinant proteins, monoclonal antibodies, antibody-drug conjugates (ADC), siRNA delivery systems, and long-acting peptide technologies. Its portfolio addresses pediatric endocrinology (growth hormone deficiency), women's health and reproductive medicine (assisted reproductive therapies and FSH products), immunology (gout treatment via Firsekibart, an IL-1β monoclonal antibody), oncology, nephrology (SLC6A19 inhibitor GenSci144), neurology (blood-brain barrier delivery), ophthalmology (VEGF blockade), and allergy/respiratory indications (allergen-specific immunotherapy through ALK-Abelló partnership). The company's franchise was built on launching the world's first PEGylated long-acting growth hormone (JinsaiZeng) in 2014, establishing 10+ years of category leadership in reduced-frequency dosing.

GeneScience commercializes products through a multi-channel go-to-market model: direct hospital and institutional sales in China, digital healthcare platform partnerships with Alibaba Health and JD Health, exclusive distribution rights for ALK's allergen desensitization products in mainland China, and international licensing arrangements — notably the December 2025 exclusive license with Yarrow Bioscience (an RTW affiliate) for GenSci098, a TSHR antagonist monoclonal antibody, valued at USD 1.365 billion in total deal value. The company also operates a wholly-owned subsidiary FindCare for children's nutritional supplements (with 2017 Nobel laureate Jeffrey C. Hall engaged as Chief Medical Officer) and has a related entity 金赛迪科 focused on women's health, while overseas expansion is anchored by a Singapore subsidiary, Shanghai Saizeng Medical Technology Pte. Ltd.

The company invests 26.5% of annual sales revenue into R&D as of 2025, maintains 80+ pipeline candidates and 30+ commercial products, and pursues international recognition through FDA clinical trial approvals across multiple programs. Revenue is generated through pharmaceutical product sales (domestic and export), licensing royalties (led by the Yarrow arrangement), and overseas commercialization via partnerships — though specific revenue is not publicly disclosed due to consolidation into its parent's financial reporting.

Name

GeneScience Pharmaceuticals Co., Ltd.

Legal name

长春金赛药业有限责任公司

Website

https://gensci-china.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

1–10 employees

Short description

GeneScience Pharmaceuticals is a Chinese biopharmaceutical company (founded 1998, subsidiary of Changchun High-Tech) developing long-acting biologics including growth hormones, fertility treatments, immunology drugs, and oncology therapies for global healthcare institutions and patients.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Biopharmaceutical products
• Recombinant growth hormone
• Long-acting biologics
• Monoclonal antibody therapy
• Fertility treatments

Headquarters

HQ city

Changchun, Jilin

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: GeneScience generates revenue through the sale of innovative biopharmaceutical products including growth hormones, reproductive health drugs, immunology products, and oncology treatments in domestic and international markets.
2. Licensing and BD Partnerships: The company earns revenue through strategic licensing agreements with international partners, including the 2025 exclusive license agreement with Yarrow Bioscience for GenSci098, valued at USD 1.365 billion.
3. Product Export/Overseas Commercialization: Revenue generated from overseas markets through partnerships and direct commercialization of innovative drugs

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

GeneScience Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and commercializes innovative biologics and small molecule drugs with a focus on recombinant human growth hormones, reproductive health therapies, immunology products, and oncology treatments. Its portfolio includes PEGylated long-acting growth hormone injections, FSH fertility drugs, an IL-1β monoclonal antibody for gout, allergen-specific immunotherapy products, ADC oncology candidates, medical devices (electronic injection pens), and licensed aesthetic medicine and nutritional supplement brands.

Product overview

GeneScience Pharmaceuticals Co., Ltd. (长春金赛药业有限责任公司) is a biopharmaceutical company with a diversified product portfolio spanning: (1) Core pharmaceutical products including growth hormone therapies (金赛增®, 赛增® - long-acting and short-acting somatropin), reproductive health drugs (金赛恒®, 金赛佳® - FSH products), gout treatment (金蓓欣®/伏欣奇拜单抗), allergy immunotherapy (安脱达®, 安刺®), and oncology supportive care (美适亚®); (2) Medical devices including electronic injection pens for growth hormone administration; (3) Nutritional supplements under the FindCare brand (赖氨酸成长系列, PS脑营养胶囊) developed with Nobel laureate Jeffrey C. Hall; (4) Aesthetic medicine products under the Neauvia brand (hyaluronic acid fillers and devices). The company operates across therapeutic areas including pediatric endocrinology, women's health, nephrology, oncology, immunology, and allergy/respiratory diseases.

Differentiator

Problem solved

Functional benefit

Brands

• FindCare (金赛健康): Children's nutritional supplement brand applying Nobel laureate research on circadian rhythm, developed in collaboration with 2017 Nobel laureate Jeffrey C. Hall. Products include lysine growth supplements, PS brain nutrition capsules, and other child health nutritional products.
• 金妍迪科
• 金派格药业 (GenPeg)

Quantifiable outcome

• 26.5% of annual sales revenue invested in R&D (2025)
• +3 more outcomes

Named customers1 record

Segments8 records

Ideal customer profiles3 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Twelve partnerships are on record, tiered flagship, core and strategic.

• Yarrow Bioscience, Inc. (RTW旗下公司)flagshipStrategic or Co-development Partner · 15 December 2025Exclusive license agreement granting Yarrow Bioscience rights to develop and commercialize GenSci098 (YB-101), a humanized TSHR antagonistic monoclonal antibody, outside Greater China. Total deal value of USD 1.365 billion including upfront, milestone, and royalty payments. This represents GeneScience's largest overseas licensing deal to date.
• ALK-Abelló A/ScoreStrategic or Co-development Partner · 17 September 2025Partnership for allergen-specific immunotherapy (AIT) products in China. GeneScience received exclusive distribution rights for 3 desensitization treatment products developed by ALK in mainland China (excluding Hong Kong, Macau, Taiwan). Also includes joint development collaboration forAIT products.
• TWi Pharmaceuticals, Inc.coreChannel Partner/ Reseller/ DistributorExclusive import and distribution agreement for Meishiya (megestrol acetate oral suspension) in mainland China, Hong Kong, Macau, and Singapore through GeneScience's Singapore subsidiary.
• Alibaba Health (阿里健康)strategicGTM or Marketing PartnerStrategic cooperation agreement for digital healthcare and smart medical services to enhance product distribution and patient access.
• JD Health (京东健康)strategicGTM or Marketing PartnerStrategic cooperation for digital healthcare and online pharmaceutical distribution partnership.
• Fudan Health (复星健康)strategicStrategic or Co-development PartnerComprehensive strategic cooperation to build a new medical healthcare ecosystem for women's and children's health.
• Partex AIcoreTechnology or IntegrationStrategic partnership with global AI company Partex AI to accelerate drug R&D and overseas commercialization through AI-powered drug discovery and data analytics.
• Shanghai Jiao Tong UniversitycoreStrategic or Co-development PartnerJoint establishment of 'Digital Medical Innovation Lab' for collaborative research in digital health and medical technology development.
• Zhejiang UniversitycoreStrategic or Co-development PartnerCo-established Children's Health Research Center with Zhejiang University for joint research in pediatric health.
• Tsinghua UniversitycoreStrategic or Co-development PartnerAcademic collaboration including student practice programs and 'Jinsai Boai Scholarship' program at Tsinghua University School of Life Sciences.
• Peking UniversitycoreStrategic or Co-development PartnerAcademic collaboration including 'Jinsai Boai Scholarship' program and sponsorship of campus activities at Peking University School of Life Sciences.
• Jeffrey C. Hall (2017 Nobel Laureate)flagshipStrategic or Co-development PartnerNobel Prize laureate serving as Chief Medical Officer for FindCare brand, bringing breakthrough circadian rhythm research to children's nutrition product development.

Scale indicators7 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Tonghua Dongbao Pharmaceutical: China's leading domestic competitor in recombinant human growth hormone and insulin. Both companies compete directly in the Chinese pediatric endocrinology market with biosimilar and long-acting growth hormone products, and both are pursuing diabetes/obesity expansion.
• BioMarin Pharmaceutical: Specialty biologics developer focused on rare diseases, enzyme replacement therapies, and gene therapy. Comparable in biologics-first development model, high R&D intensity, and focus on underserved therapeutic areas — though BioMarin has more advanced global commercialization infrastructure.
• Organon: Women's health-focused biopharma spun out of Merck, with established reproductive health, contraception, and fertility franchises. Directly comparable in the women's health and reproductive medicine therapeutic area that GeneScience is targeting through 金嫣迪科 and its FSH portfolio.
• Ascendis Pharma: Directly comparable developer of long-acting biologics using TransCon (transient conjugation) technology for growth hormone (Skytrofa) and endocrine rare diseases. Both companies compete head-to-head on once-weekly growth hormone and ultra-long-acting peptide/antibody platforms targeting the same pediatric endocrinology and endocrinology markets.
• Ferring Pharmaceuticals: Private Swiss biopharmaceutical company specializing in reproductive health (including FSH products for ART), gastroenterology, and urology. Directly comparable in the FSH/ART franchise and in women's health lifecycle coverage that GeneScience's subsidiary 金嫣迪科 targets.

Regional players

• Hansoh Pharmaceutical: Leading Chinese innovative drug company with strong R&D pipeline in oncology, CNS, and metabolic diseases. Comparable as a Chinese-headquartered biopharma pursuing international out-licensing deals and competing for talent, regulatory, and capital in the same domestic ecosystem.
• 3SBio: Chinese biopharmaceutical company with leading positions in nephrology (epoetin), oncology, and autoimmune biologics. Comparable in being a Chinese-headquartered biologics specialist with multiple therapeutic area exposure and ambitions for international expansion through licensing.
• Innovent Biologics: Chinese biologics innovator with oncology (PD-1 leadership via Tyvyt/sintilimab) and metabolic disease franchises. Comparable as a Chinese biopharma pursuing global out-licensing partnerships and building international regulatory capabilities through FDA and EMA submissions.

Broad incumbents

• Ipsen: French specialty pharma with strong endocrinology and oncology franchises, including growth disorders and rare disease biologics. Comparable in therapeutic area mix (endocrine + oncology) and in international specialty biologics commercialization that GeneScience is building toward.
• Novo Nordisk: Global market leader in growth hormone (Norditropin) and a major player in reproductive health and obesity. Directly competes with GeneScience in pediatric endocrinology internationally and represents the benchmark for long-acting biologics development in endocrine diseases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/genescience-pharmaceuticals-co-ltd-

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GeneScience Pharmaceuticals Co., Ltd.